论文部分内容阅读
据统计,75％50岁以上男性患有不同程度的良性前列腺肥大症(BPH),而80岁以上25％的男性则需切除前列腺,这为药物治疗BPH症,开发抗BPH症药物打下良好的市场前景。非那甾胺是该类化合物中第1个被批准上市的治疗BPH症药物,目前已分别在英、美、意上市,预计将在日本及其它欧洲国家上市。上市第1年(1992年)即被医药商业界评为
It is estimated that 75% of men over the age of 50 suffer from benign prostatic hyperplasia (BPH) to some extent, while 25% of men over the age of 80 are required to have their prostate removed. This is a good way to treat BPH with drugs and to develop anti-BPH drugs market expectation. Finasteride is the first of these compounds is approved for the listing of the treatment of BPH disease drugs, has been listed in Britain, the United States, Italy, is expected to be listed in Japan and other European countries. Listed in the first year (1992) that the pharmaceutical business community as